CARsgen's Satri-cel data published in Lancet, presented at ASCO

CARsgen Therapeutics Holdings Limited announced positive research results for its satri-cel (CT041) therapy, a Claudin18.2-specific CAR T-cell product candidate. The results from the pivotal Phase II clinical trial (CT041-ST-01) in China, evaluating satri-cel in patients with Claudin18.2-positive, advanced gastric/gastroesophageal junction cancer, have been published in The Lancet and presented at the ASCO Annual Meeting. The published article is titled "Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial”. CARsgen is also conducting other trials in China and North America for gastric and pancreatic cancers. Satri-cel has been granted Priority Review and Breakthrough Therapy Designation by China's NMPA. It has also been granted Regenerative Medicine Advanced Therapy designation and Orphan Drug designation by the U.S. FDA.